AG
ATXS

Artal Group’s Astria Therapeutics ATXS Stock Holding History

Artal Group’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-884,214
Closed -$12.4M – 117
2024
Q1 		$12.4M Buy
+884,214
New +$11M 0.32% 39
2022
Q4 		– Sell
-33,333
Closed -$301K – 132
2022
Q3 		$301K Hold
33,333
– – 0.01% 131
2022
Q2 		$100K Hold
33,333
– – 0.01% 134
2022
Q1 		$224K Hold
33,333
– – 0.01% 135
2021
Q4 		$180K Hold
33,333
– – ﹤0.01% 150
2021
Q3 		$295K Buy
+33,333
New +$319K 0.01% 145

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Artal Group's ATXS Position: Q2 2024 in Review

Artal Group sold out of Astria Therapeutics (ATXS) in Q2 2024, closing a stake of 884,214 shares — an estimated $12.4M sold.

Artal Group first reported a position in ATXS in Q3 2021 and held it in 6 quarters. The position peaked at $12.4M in Q1 2024. 100 funds tracked by Wall St. Rank hold ATXS as of Q2 2024.

  • Artal Group reported no remaining Astria Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Artal Group sold 884,214 Astria Therapeutics shares in Q2 2024, an estimated $12.4M.
  • Artal Group first reported a position in Astria Therapeutics in Q3 2021 and held it in 6 quarters.
  • Artal Group's Astria Therapeutics position peaked at $12.4M in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2024.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.